Hepatobiliary & Colorectal Surgery

Management of biliary complications in immunocompromised patients requires tailored timing. In neutropenic, thrombocytopenic patients with cholecystitis and choledocholithiasis, initial conservative management with antibiotics can be effective, particularly when spontaneous stone passage occurs [e10735-c9, e13736-c13]. For gallstone pancreatitis, early ERCP is typically reserved for cases with persistent biliary obstruction or cholangitis, as many patients improve without intervention [e10735-c10, e13736-c14]. If amylase and lipase trend downward, the stone has likely passed and cholecystectomy can proceed; rising levels at 24 hours indicate impaction requiring ERCP [e13736-c9, e13736-c10]. Cholecystectomy timing should be based on clinical improvement rather than complete biochemical normalization, with intraoperative cholangiogram and ERCP coordinated as needed [e10735-c11, e13736-c15]. Rectal cancer management has evolved significantly. With optimized surgery, imaging, and patient selection, local recurrence rates should be under 10%; Cleveland Clinic achieved approximately 3% over the last decade . MRI is 90–mid-90s percent accurate for T staging and high 80s–90% for nodal staging . Total mesorectal excision should achieve 1–2 millimeter circumferential resection margins with minimal blood loss (approximately 5 mL) in the correct plane [e13749-c11, e13749-c12]. Neoadjuvant therapy is indicated for T3 or node-positive tumors; stage I upper-third tumors may omit it [e13749-c13, e13749-c14]. Transanal resection (for T1 tumors <2 cm, <1/3 circumference) carries 18% local recurrence and is generally reserved for patients unfit for radical resection [e13749-c15, e13749-c16, e13749-c17].